CalcMyPeptide
Khavinson BioregulatorAlso known as: Epithalamine, Natural Epitalon extract

Epithalamin

Polypeptide extract from bovine pineal gland — the natural Cytomax predecessor to synthetic Epitalon. Used in Khavinson's landmark mortality study demonstrating extended lifespan in elderly cohorts.

Half-Life
~3 hours
Dose Range
5-10 mg IM
Frequency
1× daily for 10-20 day cycles
Vial Sizes
5 mg, 10 mg

🔬 Mechanism of Action

Epithalamin is the original natural polypeptide extract from bovine pineal gland, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It is the Cytomax predecessor to synthetic Epitalon (Ala-Glu-Asp-Gly). Epithalamin contains the natural Epitalon tetrapeptide along with additional pineal-derived peptides and cofactors. Like Epitalon, it activates telomerase reverse transcriptase (hTERT) expression in human somatic cells, potentially extending replicative capacity. Epithalamin modulates melatonin synthesis via AANAT (arylalkylamine N-acetyltransferase) gene expression in pinealocytes, restoring circadian melatonin rhythms that decline with aging. In Khavinson's landmark 15-year mortality study of elderly patients, Epithalamin + Thymalin treatment produced a 46% reduction in mortality compared to controls.

Source: PMID: 12937682

📜Background & History

Epithalamin holds a unique position in bioregulator history as the preparation used in Khavinson's most famous clinical trial — the 15-year mortality study published in 2003. In this study, elderly patients (60-80 years) receiving annual courses of Epithalamin + Thymalin showed 46% lower mortality compared to controls. Epithalamin is extracted from bovine pineal glands and is the natural multi-peptide precursor from which synthetic Epitalon (AEDG) was later isolated and characterized.

🎯 Research Use Cases

  • Longevity research
  • Telomerase activation
  • Circadian rhythm restoration
  • Melatonin production support
  • Anti-aging protocols

💉 Dosing Protocol

Typical Dose5-10 mg IM
Frequency1× daily for 10-20 day cycles
Half-Life~3 hours
Common Vial Sizes5 mg, 10 mg

🧪 Reconstitution Example

Vial
10 mg
Water
2 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 5000 mcg = 100 units on a 100-unit insulin syringe

⚠️Safety & Considerations

Well-tolerated in long-term Russian clinical studies spanning 15+ years. Side effects minimal in published studies. The natural extract may contain batch-to-batch variability compared to synthetic Epitalon. Available in Russia as an injectable preparation.

Interactions & Contraindications

Well-tolerated in long-term clinical use. May interact with exogenous melatonin supplementation. Standard injectable protocol in Russian clinical practice.

🔗Synergies & Common Stacks

Epithalamin is the natural extract, Epitalon is the purified synthetic tetrapeptide. Both target pineal function and telomerase but through slightly different compositions.

The Epithalamin + Thymalin combination is the original Khavinson longevity protocol that showed 46% mortality reduction in the 15-year study.

Epithalamin (injectable) and Endoluten (oral capsule) both originate from pineal tissue — different delivery forms of similar bioactive peptides.

📊 Dosing Quick Reference

Epithalamin— Dosing Guide
Dose Range
5-10 mg IM
Half-Life
~3 hours
Frequency
1× daily for 10-20 day cycles
Route
Subcutaneous
5 mg vial10 mg vial
💧 2 mL BAC water📐 5 mg/mL concentration💉 50 mcg/unit (100u syringe)
Khavinson Bioregulatorcalcmypeptide.com

Frequently Asked Questions

Is Epithalamin the same as Epitalon?
Not exactly. Epithalamin is the natural polypeptide extract from bovine pineal gland containing Epitalon (AEDG) plus other pineal peptides. Epitalon is the synthetic, purified tetrapeptide Ala-Glu-Asp-Gly. Both activate telomerase, but Epithalamin is a broader preparation that was used in the original clinical studies.
What was Khavinson's mortality study?
A 15-year longitudinal study showing elderly patients receiving Epithalamin + Thymalin had 46% lower mortality than controls. This landmark study (published 2003) is the primary clinical evidence for peptide bioregulator anti-aging effects.